Abstract
Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Current Drug Safety
Title:Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Volume: 8 Issue: 1
Author(s): Antonio Siniscalchi, Luca Gallelli, Simona Loizzo, Avenoso Tiziana, Emilio Russo and Giovambattista De Sarro
Affiliation:
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Abstract: Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Export Options
About this article
Cite this article as:
Siniscalchi Antonio, Gallelli Luca, Loizzo Simona, Tiziana Avenoso, Russo Emilio and Sarro Giovambattista De, Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome, Current Drug Safety 2013; 8 (1) . https://dx.doi.org/10.2174/1574886311308010010
DOI https://dx.doi.org/10.2174/1574886311308010010 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology Editorial [Hot Topic: Recent Developments in the Drug Discovery of Epilepsy (Guest Editor: Waquar Ahsan)]
Current Topics in Medicinal Chemistry Characterization of a New Positive Allosteric Modulator of AMPA Receptors - PAM-43: Specific Binding of the Ligand and its Ability to Potentiate AMPAR Currents
Current Molecular Pharmacology Integration of <sup>18</sup>FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Current Alzheimer Research Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Pharmacokinetic Studies in Infants Using Minimal-Risk Study Designs
Current Clinical Pharmacology Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents Antiepileptic Drugs During Pregnancy: Pharmacokinetics and Transplacental Transfer
Current Pharmaceutical Biotechnology Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
Current Alzheimer Research The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Parallel Computing for Brain Simulation
Current Topics in Medicinal Chemistry Zinc-Permeable Ion Channels: Effects on Intracellular Zinc Dynamics and Potential Physiological/Pathophysiological Significance
Current Medicinal Chemistry Investigating Mitochondrial Dysfunction to Increase Drug Safety in the Pharmaceutical Industry
Current Drug Targets Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets